Ardelyx (ARDX) Cash from Operations (2013 - 2026)
Ardelyx's (ARDX) quarterly Cash from Operations came in at 32237000.0 in Q1 2026, up 16.17% YoY from 27748915.75 in Q1 2025, and down 253.87% on a QoQ basis from 20951000.0 in Q4 2025.
Ardelyx (ARDX) Cash from Operations (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Cash from Operations data on file, last reported at 32237000.0 in Q1 2026.
- Quarterly Cash from Operations rose 16.17% year-over-year to 32237000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36263000.0 (up 23.73% YoY) and the FY2025 annual result came in at 42483000.0, up 5.19% from the prior year.
- Cash from Operations retreated to 32237000.0 in Q1 2026, from 20951000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 20951000.0 in Q4 2025 to a low of 44795000.0 in Q1 2023.
- A 5-year average of 16428823.53 and a median of 21467000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 161.03% — and 2024, when it jumped 212.53%.
- Tracing ARDX's Cash from Operations over 5 years: stood at 14284000.0 in 2022, then slumped by 161.03% to 8718000.0 in 2023, then jumped by 212.53% to 9810000.0 in 2024, then jumped by 113.57% to 20951000.0 in 2025, then sank by 253.87% to 32237000.0 in 2026.
- The last three Cash from Operations figures came in at 32237000.0 (Q1 2026), 20951000.0 (Q4 2025), and 365000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -6.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.40 Mn |
| Jun 30, 2026 | -6.40 Mn |
| Mar 31, 2026 | -32.24 Mn |
| Mar 31, 2026 | -32.24 Mn |
| Dec 31, 2025 | 20.95 Mn |
| Dec 31, 2025 | 20.95 Mn |
| Sep 30, 2025 | 365,000.00 |
| Sep 30, 2025 | 365,000.00 |
| Jun 30, 2025 | -25.34 Mn |
| Jun 30, 2025 | -25.34 Mn |
| Mar 31, 2025 | -38.46 Mn |
| Mar 31, 2025 | -38.46 Mn |
| Dec 31, 2024 | 9.81 Mn |
| Dec 31, 2024 | 9.81 Mn |
| Sep 30, 2024 | 501,000.00 |
| Sep 30, 2024 | 501,000.00 |
| Jun 30, 2024 | -19.40 Mn |
| Jun 30, 2024 | -19.40 Mn |
| Mar 31, 2024 | -35.72 Mn |
| Mar 31, 2024 | -35.72 Mn |